The strong PFS and ORR data support potential accelerated approval; traders should monitor for NDA submission in H2 2026 and upcoming data presentation at a major medical conference. This could be a catalyst for significant upside given the lack of effective treatments in metastatic uveal melanoma.
Price Chart
Executive Summary
IDEAYA Biosciences announced positive Phase 2/3 clinical trial results for darovasertib in combination with crizotinib in first-line HLA-A*02:01-negative metastatic uveal melanoma, showing a 58% reduction in risk of progression and significantly improved median progression-free survival (6.9 vs 3.1 months). The company plans to submit a New Drug Application (NDA) in the second half of 2026.
Key Facts
- Darovasertib combination met primary endpoint of statistically significant improvement in median PFS (6.9 months vs 3.1 months) with hazard ratio of 0.42 (p < 0.0001)
- ORR was 37.1% in the darovasertib arm vs 5.8% in the investigator choice therapy arm (p < 0.0001)
- 5 complete responses observed in darovasertib arm, none in control arm
- Median DOR was 6.8 months in the darovasertib arm
- OS data not mature but early trend favoring darovasertib combination
- Safety profile manageable with Grade 3+ adverse events including diarrhea, syncope, and hypotension
- NDA submission targeted for second half of 2026
Financial Impact
Potential blockbuster approval in a high-unmet-need orphan indication with no current standard of care; market opportunity estimated at $500M+ annual peak sales
Risk Factors
- OS data not mature, creating uncertainty about overall survival benefit
- FDA may require confirmatory trial post-approval
- Competition from other targeted therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151893 |
| Document: 0001193125-26-151893-index-headers.html | 0001193125-26-151893 |
| Document: 0001193125-26-151893-index.html | 0001193125-26-151893 |
| Document: 0001193125-26-151893.txt | 0001193125-26-151893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $36.11 $39.95 | ▲ +10.63% | ▲ +11.87% | $37.34 (+3.41%) |
Jun 23, 2026 14w ago | 8-K | $36.28 $35.00 | ▼ −3.53% | ▼ −5.46% | $37.34 (+2.92%) |
Jun 10, 2026 16w ago | 8-K | $28.84 $37.28 | ▼ −29.26% | ▼ −27.37% | $37.34 (−29.47%) |
Jun 9, 2026 16w ago | 424B5 | $27.60 $37.28 | ▼ −35.07% | ▼ −31.45% | $37.34 (−35.29%) |
Jun 8, 2026 16w ago | 424B5 | $28.07 $40.51 | ▼ −44.32% | ▼ −42.87% | $37.34 (−33.02%) |
Jun 3, 2026 17w ago | 8-K | $28.40 $37.65 | ▲ +32.57% | ▲ +33.57% | $37.34 (+31.48%) |
May 5, 2026 21w ago | 8-K | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.34 (+29.92%) |
May 5, 2026 21w ago | 424B5 | $28.74 $28.40 | ▼ −1.18% | ▼ −3.96% | $37.34 (+29.92%) |
Apr 13, 2026 24w ago | 8-K | $32.82 $28.13 | ▼ −14.29% | ▼ −22.02% | $37.34 (+13.77%) |
Apr 9, 2026 25w ago | 8-K | $31.00 $28.74 | ▼ −7.29% | ▼ −14.86% | $37.34 (+20.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access